Adagio Medical Holdings (ADGM) Q2 2026 earnings summary

Executive summary

• Focused on developing proprietary Ultra-Low Temperature Ablation (ULTA) technology for ventricular tachycardia (VT) treatment, with pivotal clinical trials completed and FDA PMA submission for vCLAS system in May 2026.

• Achieved a major milestone with the first patient treated using the next-generation vCLAS Ultra catheter under FDA Expanded Access.

• Presented pivotal FULCRUM-VT trial results showing strong safety and efficacy for ULTA technology.

• No revenue generated in Q2 2026 due to paused European commercial activities; operations centered on R&D and regulatory milestones.

• Net loss increased to $6.7M for Q2 2026 and $13.7M for the first half of 2026, reflecting ongoing investment in clinical and product development.

Financial highlights

• Cash and cash equivalents were $7.7M as of June 30, 2026, down from $17.1M at year-end 2025.

• Accumulated deficit reached $109.4M as of June 30, 2026.

• Research and development expenses were $2.5M for Q2 2026 (up 24% YoY), $5.2M for the first half (down 8% YoY).

• Selling, general, and administrative expenses were $2.5M for Q2 2026 (up 3% YoY), $4.9M for the first half (down 17% YoY).

• Net loss widened to $6.7M ($0.30 per share) for Q2 2026, compared to $3.9M ($0.26 per share) YoY.

Outlook and guidance

• Current cash expected to fund operations into Q4 2026; substantial doubt exists about ability to continue as a going concern beyond that period.

• Additional capital will be required to support ongoing R&D, regulatory, and potential commercialization activities.

• Focus remains on executing clinical and regulatory milestones, including FDA review of the PMA application.

• Management is pursuing equity/debt financing, regulatory approvals, and cost-cutting measures.